I maintain a Buy rating on Humana due to robust revenue growth and expanding margins, driven by strong demand in core markets. Management's guidance for the next quarter remains optimistic, supported by new product launches and recent customer wins. Valuation remains attractive relative to peers, with the stock trading at a discount despite superior earnings momentum and free cash flow generation.

Amazon plans to expand its same-and-next-day delivery service to tens of millions of American consumers. [contact-form-7] The expansion, targeting more than 4,000 smaller cities, towns and rural communities, is slated to happen by the year's end, the eCommerce giant announced Tuesday (June 24).

Nike Inc (NYSE:NKE, ETR:NKE) shares are trading at near-decade lows, but Jefferies analysts are urging investors to look beyond the upcoming fourth quarter earnings pain and “just buy it.” The analysts repeated their ‘Buy' rating on Nike with a price target of $115, representing upside of nearly 90% from current levels, and declared that the company has reached its fundamental trough.

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Vera Bradley, Inc. (NASDAQ: VRA) resulting from allegations that Vera Bradley may have issued materially misleading business information to the investing public.

I maintain my Hold rating on Constellation Brands, expecting continued weakness and negative sentiment to persist in the near term. The beer segment remains the main growth engine, but guidance has been lowered significantly, reflecting ongoing macroeconomic and consumer headwinds. Wine and spirits continue to struggle with double-digit revenue declines; I see little evidence of a turnaround or effective premiumization so far.

Teladoc (TDOC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Eagle Bancorp, Inc. (NASDAQ: EGBN) resulting from allegations that Eagle Bancorp may have issued materially misleading business information to the investing public.

JetBlue rolls out in-app bag tracking and Apple AirTag integration to enhance its baggage service and boost customer confidence.

SVOL's portfolio is now more conservative, shifting from leveraged equities to bonds, reducing downside risk in future corrections. The VIX term structure has normalized to contango, allowing SVOL to generate higher premiums and sustain a yield near 20%. Despite improved positioning, I remain speculatively bearish on SVOL due to overvalued US stocks and persistent macroeconomic risks.

With steady earnings, digital investments, and strong liquidity, is BPOP a Smart Buy Now? Let's find out.

After plunging in January on fears that China's DeepSeek AI could undercut its dominance, the Nvidia Corp. NVDA stock has not only recouped the losses—it's now flashing a powerful technical signal that has historically preceded massive rallies.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of Apple Inc. (NASDAQ: AAPL) securities between June 10, 2024 and June 9, 2025, both dates inclusive (the “Class Period”). Apple is a technology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that A.

Guggenheim Partners on Monday initiated coverage on Amylyx Pharmaceuticals, Inc. AMLX, noting the company is poised to open post-bariatric hypoglycemia's (PBH) blockbuster potential.

The National Transportation Safety Board is set to vote on likely causes of January 2024 accident and make recommendations.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of PetMed Express, Inc. (“PetMed” or the “Company”) (NASDAQ: PETS) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PETMED EXPRESS, INC. (PETS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On June 10, 2025, PetMed disclosed that it would be delaying the.

Zscaler is on a strong path to reach the $5 billion in ARR. The emerging growth categories are one of the key driving forces in reaching this milestone. The company's revamped GTM strategy is another key enabler to drive ARR growth. Additionally, new initiatives, such as the Z-Flex purchasing program, are driving strong ARR growth. ZS is witnessing strong demand from enterprise customers. It has also been able to expand its customer base, providing further scope for upsell opportunities.

Redesigning and repricing of products and services amid a low rate environment are likely to help Zacks Life Insurance industry players like AAGIY, MFC, SLF, AVVIY and NNGRY. These companies are investing heavily in digitization.

Upgrading Lumen Technologies from hold to buy, raising LUMN stock's price target to $5.64, representing a 33% upside, based on improved cost efficiency and strategic clarity. The confirmed sale of Lumen's mass markets fiber business to AT&T brings in $5 billion in cash, reduces debt by $4.8 billion, and allows the company to focus on enterprise. Despite ongoing revenue declines, Lumen's “Grow” portfolio has increased nearly 10% year-over-year, now comprising 48% of total revenue, showing strong traction in enterprise services.

I am moving Compass Pathways plc from Strong Buy to Hold after phase 3 COMP005 data, as results met endpoints but disappointed market expectations. Upcoming catalysts include 26-week COMP006 phase 3 data in 2H 2026 and ongoing PTSD and anorexia programs, but risks remain if future data underwhelms. The treatment resistant depression market in the 7 major markets is expected to reach $6.70 billion by 2035.

I maintain my Buy rating on Ligand Pharmaceuticals due to its strong growth trajectory and diversified portfolio. Ligand offers investors exposure to dozens of therapies, reducing risk and increasing upside potential. LGND's business model supports sustainable revenue through royalties and partnerships with leading pharma firms.